SCHEMBL4075279

SCHEMBL4075279

COC(=O)Cc1cc(-c2ccccc2)nc(OC)c1C#N

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 9/20 0.62
KDM4E B2RXH2 4/20 0.52
MAPT P10636 3/20 0.52
ALDH1A1 P00352 3/20 0.52
NPC1 O15118 1/20 0.52
GAA P10253 1/20 0.52
PIM1 P11309 3/20 0.51
POLB P06746 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MEN1 O00255 2/20 0.48
HPGD P15428 2/20 0.48
KMT2A Q03164 2/20 0.48
USP2 O75604 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069859 0.87 SQOR (0.50) SQORKDM4EMAPTALDH1A1PIM1
SCHEMBL4064410 0.81 SQOR (0.71) SQORKDM4EMAPTALDH1A1NPC1
SCHEMBL4070239 0.80 HSD17B10 (0.46) KDM4EMAPTALDH1A1GAAPOLB
SCHEMBL4065725 0.78 MAPK8 (0.43) SQORKDM4EMAPTALDH1A1GAA
SCHEMBL22215650 0.78 SQOR (1.00) SQORKDM4EMAPTALDH1A1NPC1
SCHEMBL4073517 0.77 ADORA1 (0.48) SQORKDM4EMAPTALDH1A1GAA
SCHEMBL4069790 0.77 MAPK8 (0.41) SQORKDM4EMAPTALDH1A1GAA
SCHEMBL4069229 0.76 WNT3A (0.41) SQORKDM4EMAPTALDH1A1NPC1
SCHEMBL4064361 0.75 SQOR (0.45) SQORKDM4EMAPTALDH1A1GAA
SCHEMBL4073012 0.75 SQOR (0.78) SQORKDM4EMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 SQOR 264/4885KDM4E 405/4885MAPT 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.